Who are SPARSENTAN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tryvio, Opsumit, Letairis, Tracleer, Ambrisentan plus Spironolactone, "Nefecon®","Ambrisentan".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sparsentan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SPARSENTAN — Competitive Intelligence Brief

SPARSENTAN (SPARSENTAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin Receptor Antagonist [EPC].

marketed Endothelin Receptor Antagonist [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

SPARSENTAN (SPARSENTAN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPARSENTAN TARGET	SPARSENTAN		marketed	Endothelin Receptor Antagonist [EPC]		2023-01-01
Tryvio	APROCITENTAN	Idorsia	marketed	Endothelin Receptor Antagonist [EPC]		2025-01-01
Opsumit	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01
Tracleer	BOSENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
Ambrisentan plus Spironolactone	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)

Recent regulatory actions (last 90 days)

2026-03-03 — Tracleer · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-15 — Tracleer · 8309126 · Formulation · US
2027-12-28 — Tracleer · 7959945 · Formulation · US

Sponsor landscape (Endothelin Receptor Antagonist [EPC] class)

· 1 drug in this class
AstraZeneca · 1 drug in this class
Gilead Sciences · 1 drug in this class
Idorsia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPARSENTAN — Competitive Intelligence Brief. https://druglandscape.com/ci/sparsentan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab